DNLI
$21.45
Net Profits | $-107.19Mn |
Denali Therapeutics Inc’s net profit fell -7.89% since last year same period to $-107.19Mn in the Q3 2024. On a quarterly growth basis, Denali Therapeutics Inc has generated -8.25% fall in its net profits since last 3-months.
EPS Estimate Current Quarter | -0.61 |
EPS Estimate Current Year | -0.61 |
Denali Therapeutics Inc’s earning per share (EPS) estimates for the current quarter stand at -0.61 - a 11.59% jump from last quarter’s estimates.
Denali Therapeutics Inc’s earning per share (EPS) estimates for the current year stand at -0.61.
Earning Per Share (EPS) | -0.63 |
Denali Therapeutics Inc’s earning per share (EPS) jumped 12.5% since last year same period to -0.63 in the Q3 2024. This indicates that the Denali Therapeutics Inc has generated 12.5% annual rate of jump in its earning per share (EPS) in the last 4 quarters.
Earnings Date | Estimated EPS | Reported EPS | Surprise % |
---|---|---|---|
2024-11-06 | -0.61 | -0.63 | -3.28% |
2024-05-07 | -0.7 | -0.78 | -11.43% |
2024-08-01 | -0.69 | -0.59 | 14.49% |